Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

Tumour necrosis factor (TNF) is a classical, pleiotropic pro-inflammatory cytokine. It is also
the first 'adipokine'described to be produced from adipose tissue, regulated in obesity and …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
worldwide. NAFLD stages range from simple steatosis (NAFL) to non-alcoholic …

Many studies have reported that metabolic dysfunction is closely involved in the complex
mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which …

Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing
challenge in terms of prevention and treatment. Despite its high prevalence, only a small …

Tumour necrosis factor-α (TNF) is a multifunctional cytokine. First recognized as an
endogenous soluble factor that induces necrosis of solid tumours, TNF became increasingly …

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different
entities sharing common clinical and physio-pathological features, with insulin resistance …

Accumulating evidence indicates that obesity is closely associated with an increased risk of
metabolic diseases such as insulin resistance, type 2 diabetes, dyslipidemia and …